Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAHWLR)

Drug Name
MGD007 Drug Info
Indication
Disease Entry ICD 11 Status REF
Colorectal cancer 2B91.Z Phase 1/2 [1]
Metastatic colorectal cancer 2B91 Phase 1 [2]
Cross-matching ID
TTD Drug ID
DMAHWLR

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting T-cell surface glycoprotein CD3 gamma (CD3G)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tebentafusp DMUJ1WV Gastric cancer 2B72 Approved [4]
Teplizumab DMZ3P6C Type-1 diabetes 5A10 Approved [5]
Ertumaxomab DM5Z3VP Breast cancer 2C60-2C65 Phase 2 [6]
MT-110 DMPCUN5 Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
Autologous T-cell therapy DMOAET3 Prostate cancer 2C82.0 Phase 1 [8]
MEDI-565 DMFWPLQ Gastrointestinal cancer 2C11 Phase 1 [3]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Targeting Cell surface A33 antigen (GPA33)
Drug Name Drug ID Indication ICD 11 Highest Status REF
KRN-330 DMA5B1S Colorectal cancer 2B91.Z Phase 1/2 [9]
HuA33 DMB3LQU Colorectal cancer 2B91.Z Phase 1 [10]
Radiolabelled-huA33 DMIEJ0W Colorectal cancer 2B91.Z Phase 1 [10]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cell surface A33 antigen (GPA33) TT96HUR GPA33_HUMAN Modulator [3]
T-cell surface glycoprotein CD3 gamma (CD3G) TTV3XPL CD3G_HUMAN Modulator [3]

References

1 ClinicalTrials.gov (NCT03531632) MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6 Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012 Sep-Oct;4(5):614-22.
7 EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res. 2012 Jan 15;18(2):465-74.
8 Antitumor activities of PSMA CD3 diabodies by redirected T-cell lysis of prostate cancer cells. Immunotherapy. 2013 Jan;5(1):27-38.
9 Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer. Invest New Drugs. 2014 Aug;32(4):682-90.
10 (124)I-huA33 antibody PET of colorectal cancer. J Nucl Med. 2011 Aug;52(8):1173-80.